Hong Kong Training Portal on
Infection Control and Infectious Disease

• Lancet Ebola Resource Centre
• New England Journal of Medicine (NEJM)

Epidemiology

• The 16th Ebola outbreak in DRC: a roadmap integrating genomics data, community voices, and past lessons (December 4, 2025)
• Ebola virus disease mathematical models and epidemiological parameters: a systematic review (August 7, 2024)
• Identifying Paucisymptomatic or Asymptomatic and Unrecognized Ebola Virus Disease Among Close Contacts Based on Exposure Risk Assessments and Screening Algorithms (September 1, 2022)
• The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018–2019 (May 29, 2019)
• Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection (February 29, 2016)

Clinical Features, Diagnosis, and Management

• UpToDate. Clinical manifestations and diagnosis of Ebola disease
• Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches (January 19, 2024)
• Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis (July 5, 2022)
• Ebola virus disease in pregnancy: a systematic review and meta-analysis (December 2, 2021)
• Pregnancy and breastfeeding in the context of Ebola: a systematic review (May 6, 2020)
• Ebola (May 6, 2020)
• Ebola virus disease (February 20, 2020)
• A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics (November 27, 2019)
• A systematic review and meta-analysis of patient data from the west Africa (2013–16) Ebola virus disease epidemic (July 5, 2019)
• Evidence-based guidelines for supportive care of patients with Ebola virus disease (October 17, 2017)
• A randomized, controlled trial of ZMapp for Ebola virus infection (October 13, 2016)
• Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days (September 1, 2016)

Complications and Sequelae

• Long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infection: a matched cohort study (July 18, 2025)
• Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long Ebola (September 6, 2023)
• Characterization of Ebola Virus–Associated Eye Disease (January 5, 2021)
• Long-lasting severe immune dysfunction in Ebola virus disease survivors (July 24, 2020)
• A Longitudinal Study of Ebola Sequelae in Liberia (March 6, 2019)
• Ebola Virus–Related Encephalitis (July 14, 2016)
• Ebola Virus Disease Complications as Experienced by Survivors in Sierra Leone (March 21, 2016)

Infection prevention and control

• Effect of a safe and dignified burial intervention on Ebola virus transmission in the eastern Democratic Republic of the Congo, 2018–19: a propensity score analysis (September 2025)
• Summary of WHO infection prevention and control guideline for Ebola and Marburg disease: a call for evidence based practice (February 26, 2024)
• Prevention and post-exposure management of occupational exposure to Ebola virus (September 15, 2023)
• Characteristics of Ebola Virus Disease Survivor Blood and Semen in Liberia: Serology and Reverse Transcription Polymerase Chain Reaction (RT-PCR) (September 7, 2020)
• A novel personal protective equipment coverall was rated higher than standard Ebola virus personal protective equipment in terms of comfort, mobility and perception of safety when tested by health care workers in Liberia and in a United States biocontainment unit (October 6, 2018)
• Ebola RNA persistence in semen of Ebola virus disease survivors (October 12, 2017)
• Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child (January 7, 2017)
• Addressing Infection Prevention and Control in the First U.S. Community Hospital to Care for Patients With Ebola Virus Disease: Context for National Recommendations and Future Strategies (May 10, 2016)

Vaccination

• Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial (September 08, 2025)
• Use of Ebola Vaccines — Worldwide, 2021–2023 (April 25, 2024)
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone (November 2023)
• Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo (August 24, 2023)
• Ebola virus disease: an update on post-exposure prophylaxis (November 15, 2017)
• Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia (October 12, 2017)
• Considerations for use of Ebola vaccine during an emergency response (September 7, 2017)  
• Toward an effective Ebola virus vaccine (January 2017)
• Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) (December 22, 2016)

Immunology

• Associations of inflammatory markers with post-acute clinical findings among survivors of Ebola virus disease with and without viral RNA shedding in the semen in Liberia: a nested case–control study (March 10, 2025)
• Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses (July 12, 2019)